GlassScriptPhysician profile
Michi E Nair
NPI 1427384429
$1,763.20
in general payments reported to CMS, 2019-2025
21 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.82 · 2022: $243 · 2023: $396 · 2024: $704 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.40 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $294.96 | 2022-2025 | |
| C. R. Bard, INC. & Subsidiaries | $174.10 | 2023-2024 | Bard Urinary Drainage Bag |
| Teleflex LLC | $166.41 | 2023 | Urolift |
| Dornier Medtech America, INC | $138.51 | 2025 | Dornier Medtech |
| Procept Biorobotics Corporation | $134.53 | 2025 | |
| Astellas Pharma US INC | $121.77 | 2023-2024 | Xtandi |
| Rochester Medical Corporation | $117.30 | 2022 | |
| 180 Medical, INC. | $115.57 | 2022-2024 | Gentlecath |
| Innovation Technologies INC | $115.14 | 2024 | Irrisept |
| Janssen Biotech, INC. | $93.03 | 2024 | Erleada |
| Antares Pharma, INC. | $55.02 | 2024-2025 | Xyosted |
| Progenics Pharmaceuticals, INC. | $45.52 | 2023-2025 | Pylarify |
| Olympus America INC. | $36.89 | 2025 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $29.35 | 2024 | |
| Accord Healthcare, INC. | $23.95 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $23.93 | 2025 | Posluma |
| Sumitomo Pharma America, INC. | $21.38 | 2025 | Gemtesa |
| Halozyme INC | $18.02 | 2023 | |
| Pfizer INC. | $17.77 | 2024 | |
| Endo Pharmaceuticals INC. | $16.23 | 2024 | Aveed, Xiaflex |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michi Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.